We further demonstrate that recombinant FGF21 ameliorates hepatic lipid and iron accumulation in this NAFLD/NASH model by downregulating the PCB-induced overexpression of hepatic LCN2. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.